223 related articles for article (PubMed ID: 30173532)
1. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
2. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
4. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
5. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
6. Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma.
Moore DC; Lavery LA
J Adv Pract Oncol; 2018 Mar; 9(2):235-240. PubMed ID: 30588358
[TBL] [Abstract][Full Text] [Related]
7. New drugs and combinations for the treatment of soft-tissue sarcoma: a review.
Somaiah N; von Mehren M
Cancer Manag Res; 2012; 4():397-411. PubMed ID: 23226072
[TBL] [Abstract][Full Text] [Related]
8. New targeted therapies in liposarcoma: state of art and future perspectives.
Franza A; Fabbroni C; Pasquali S; Casali PG; Sanfilippo R
Curr Opin Oncol; 2024 May; ():. PubMed ID: 38726840
[TBL] [Abstract][Full Text] [Related]
9. Advances in sarcoma genomics and new therapeutic targets.
Taylor BS; Barretina J; Maki RG; Antonescu CR; Singer S; Ladanyi M
Nat Rev Cancer; 2011 Jul; 11(8):541-57. PubMed ID: 21753790
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in sarcomas: challenging the challenge.
Martín Liberal J; Lagares-Tena L; Sáinz-Jaspeado M; Mateo-Lozano S; García Del Muro X; Tirado OM
Sarcoma; 2012; 2012():626094. PubMed ID: 22701332
[TBL] [Abstract][Full Text] [Related]
11. Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma.
Penniman L; Parmar S; Patel K
P T; 2018 May; 43(5):267-270. PubMed ID: 29719366
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
13. First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M; Seetharam M
Curr Treat Options Oncol; 2019 Jan; 20(1):6. PubMed ID: 30675651
[TBL] [Abstract][Full Text] [Related]
14. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients.
Fang J; Shao Y; Su J; Wan Y; Bao L; Wang W; Kong F
Ther Clin Risk Manag; 2018; 14():1527-1535. PubMed ID: 30214216
[TBL] [Abstract][Full Text] [Related]
16. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Martin-Liberal J; Pérez E; García Del Muro X
Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies for small cell lung cancer.
Yang S; Zhang Z; Wang Q
J Hematol Oncol; 2019 May; 12(1):47. PubMed ID: 31046803
[TBL] [Abstract][Full Text] [Related]
19. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
20. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
